Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency: A double-blind, placebo-controlled study

Journal of Clinical Investigation

Volumn 98, Issue 12, 1996, Pages 2706-2713

  Böger, Rainer H ^a,b   Skamira, Cord ^a   Bode Böger, Stefanie M ^a   Brabant, Georg ^a   Von Zur Mühlen, Alexander ^a   Frölich, Jürgen C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclic guanidine monophosphate; Echocardiography; Endothelium; Gas chromatography mass spectrometry; Insulin like growth factor 1

Indexed keywords

CYCLIC GMP; NITRIC OXIDE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPITUITARISM; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; URINARY EXCRETION; VASCULAR RESISTANCE;

ADULT; BLOOD PRESSURE; CARDIAC OUTPUT; CYCLIC GMP; FEMALE; GROWTH HORMONE; HEART RATE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; MALE; NITRATES; NITRIC OXIDE; RECOMBINANT PROTEINS; VASCULAR RESISTANCE;

EID: 0030454148     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119095     Document Type: Article

References (59)

1. Rosén, T., and B.A. Bengtsson. 1900. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 336:285-288.
2. Merimee, T., W. Hollander, and E. Fineberg. 1972. Studies of hyperlipidemia in the hGH-deficient state. Metabolism. 21:1053-1061.
3. Blackett, P.R., P.K. Weech, W.J. McConathy, and J.D. Fesmire. 1982. Growth hormone in the regulation of hyperlipidernia. Metabolism. 31:117-120.
4. Rosén, T., S. Edén, G. Larson, L. Wilhelmsen, and B.A. Bengtsson. 1993. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol. 128:195-200.
5. Friedman, M., S.O. Byers, R.H., Rosenman, C.H. Li, and R. Neuman. 1974. Effect of subacute administration of human growth hormone on various serum lipid and hormone levels of hypercholesterolemic and normocholesterolemic subjects. Metabolism. 23:905-912.
6. Lapidus, L., C. Bengtsson, B. Larsson, K. Pennert, E. Rybo, and L. Sjöström. 1984. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of women in Gothenburg, Sweden. Br. Med. J. 289:1257-1261.
7. Larsson, B., K. Svärdsudd, L. Welin, L. Wilhelmsen, P. Björntorp, and G. Tibblin. 1984. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. Br. Med. J. 288:1401-1404.
8. Thuesen, L., J.S. Christiansen, K. E. Sorensen, J.O.L. Jorgensen, H. Orskov, and P. Henningsen. 1988. Increased myocardial contractility following growth hormone administration in normal man. Dan. Med. Bull. 35:193-196.
9. Caidahl, K., S. Edén, and B.A. Bengtsson. 1994. Cardiovascular and renal effects of growth hormone. Clin. Endocrinol. 40:393-400.
10. Daughaday, W.H., and P. Rotwein. 1989. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 10:68-91.
11. Sacca, L., A. Cittadini, and S. Fazio. 1994. Growth hormone and the heart. Endocr. Rev. 15:555-573.
12. Krieg, R.J., F. Santos, and J.C.M. Chan. 1995. Growth hormone, insulin-like growth factor and the kidney. Kidney Int. 48:321-336.
13. Landin-Wilhelmsen, K., L. Wilhelmsen, G. Lappas, T. Rosén, G. Lindstedt, P.A. Lundberg, and B.A. Bengtsson. 1994. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin. Endocrinol. 41:351-357.
14. Bar, R.S., M. Boes, B.L. Dake, B.A. Booth, S.A. Henley, and A. Sandra. 1988. Insulin, insulin-like growth factors, and vascular endothelium. Am. J. Med. 85(Suppl. 5a):59-70.
15. Wu, H.Y., C.J. Yue, K.Y. Chyu, W.A. Hsueh, and T.M. Chan. 1994. Endothelial-dependent vascular effects of insulin and insulin-like growth factor I in the perfused rat mesenteric artery and aortic ring. Diabetes. 43:1027-1032.
16. Haylor, J., I. Singh, and A.M. El Nahas. 1991. Nitric oxide inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int. 39:333-335.
17. Tsukahara, H., D.V. Gordienko, B. Tonshoff, M.C. Gelato, and M.S. Goligorsky. 1994. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 45:598-604.
18. Moncada, S., and E.A. Higgs. 1993. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:2002-2012.
19. Radomski, M.W., and E. Salas. 1995. Nitric oxide-biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atheroslerosis. 118(Suppl.):S69-S80.
20. Böger, R.H., S.M. Bode-Böger, A. Mügge, S. Kienke, R. Brandes, A. Dwenger, and J.C. Frölich. 1995. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 117:273-284.
21. Küng, C.F., and T.F. Lüscher. 1995. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension (Dallas). 25:194-200.
22. Cooke, J.P., A.H. Singer, P. Tsao, P. Zera, R.A. Rowan, and M.E. Billingham. 1992. Antiatherosclerotic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 90:1168-1172.
23. Candipan, R.C., B. Wang, R. Buitrago, P.S. Tsao, and J.P. Cooke. 1996. Regression or progression. Dependency on vascular nitric oxide. Arterioscler. Thromb. Vasc. Biol. 16:44-50.
24. Böger, R.H., S. M. Bode-Böger, U. Gerecke, and J.C. Frölich. 1994. Long-term administration of L-arginine, L-NAME, and the exogenous NO donor molsidomine modulate urinary nitrate and cyclic GMP excretion in rats - correlation with vascular reactivity. Cardiovasc. Res. 28:494-499.
25. - excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-NAME in rats. Clin. Exp. Pharmacol. Physiol. 23:11-15.
26. Bode-Böger, S.M., R.H. Böger, H. Alfke, D. Heinzel, D. Tsikas, A. Creutzig, K. Alexander, and J.C. Frölich. 1996. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation. 93:85-90.
27. Juul, A., P. Bang, N.T. Hertel, K. Main, P. Dalgaard, K. Jörgensen, J. Müller, K. Hall, and N.E. Skakkebaek. 1994. Serum insulin-like growth factor-1 in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J. Clin. Endocrinol. Metab. 78: 744-752.
28. Uehara, Y., M. Koga, and M. Takahashi. 1995. Determination of cardiac output by echocardiography. J. Vet. Med. Sci. 57:401-407.
29. 15N-labelled analogs. J. Chromatogr. B Biomed. Appl. 661:185-191.
30. Blum, W.F., and B.H. Breier. 1994. Radioimmunoassays for IGFs and IGFBPs. Growth Regul. 4(Suppl. 1):11-19.
31. Fisher, L.D., and G. van Belle. 1993. Multiple comparisons. In Biostatistics. A Methodology for the Health Sciences. LD Fisher and G. van Belle, editors. John Wiley & Sons, New York. 596-629.
32. Ludbrook, J. 1994. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc. Res. 28:303-311.
33. Cuneo, R.C., F. Salomon, G.F. Watts, R. Hesp, and P.H. Sönksen. 1993. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism. 42:1519-1523.
34. Rosén, T., G. Johansson, J.O. Johansson, and B.A. Bengtsson. 1995. Consequences of growth hormone deficiency in adults and the benefits of recombinant growth hormone treatment. Horm. Res. (Basel). 43:93-99.
35. Wuster, C.H.R., E. Slenczka, and R. Ziegler. 1991. Erhöhte Prävalenz von osteoporose und arteriosklerose bei konventionell substituierter hypophysenvorderlappen-insuffizienz: bedarf einer zusätzlichen wachstumshormonsubstitution? Klin. Wochenschr. 69:769-773.
36. Salomon, F., R.C. Cuneo, R. Hesp, and P.M. Sönksen. 1989. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 321: 1797-1803.
37. Jörgensen, J.O.L., L. Thuesen, T. Ingemann-Hansen, S.A. Pedersen, J. Jörgensen, N.E. Skakkebaek, and J.S. Christiansen. 1989. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. I:1221-1225.
38. Whitehead, H., C. Boreham, E.M. McIlrath, B. Sheridan, L. Kennedy, A.B. Atkinson, and D.R. Hadden. 1992. Growth hormone treatment of adults with growth hormone deficiency. Results of a 13-month placebo controlled cross-over study. Clin. Endocrinol. 36:45-52.
39. Bengtsson, B.A., S. Edén, L. Lönn, H. Kvist, A. Stokland, G. Lindstedt, I. Bosaeus, J. Tölli, L. Sjöström, and O. G. P. Isaksson. 1993. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J. Clin. Endocrinol. Metab. 76:309-317.
40. Riedel, M., G. Brabant, K. Rieger, and A. von zur Mühlen. 1994. Growth hormone therapy in adults: rationales, results, and perspectives. Exp. Clin. Endocrinol. 102:273-283.
41. Rudling, M., G. Norstedt, H. Olivecrona, E. Reinér, J.A. Gustafsson, and B. Angelin. 1992. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc. Natl. Acad. Sci. USA. 89:6983-6987.
42. Cuneo, R.C., F. Salomon, C.M. Wiles, R. Hesp, and P.H. Sönksen. 1991. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J. Appl. Physiol. 7:688-694.
43. Rosén, T., G. Johansson, P. Hallgren, K. Caidahl, I. Bosaeus, and B.A. Bengtsson. 1994. Beneficial effects of 12 months replacement therapy with recombinant human growth hormone to growth hormone deficient adults. Endocrinol. Metab. 1:55-66.
44. Edén, S., O. Wiklund, J. Oscarsson, T. Rosén, and B.A. Bengtsson. 1993. Growth hormone treatment of growth hormone deficient adults results in a marked increase in lipoprotein (a) concentrations but also in increased HDL cholesterol concentrations. Arterioscler. Thromb. 13:296-301.
45. Hoffman, D.M., L. Crampton, C. Srenia, T.V. Nguyen, and K.K.Y. Ho. 1996. Short term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. J. Clin. Endocrinol. Metab. 81:1123-1128.
46. Markussis, V., S.A. Beshyah, C. Fisher, P. Sharp, A.N. Nicolaides, and D.G. Johnston. 1992. Detection of premature atherosclerosis by high-resolution ultrasound in symptom-free hypopituitary adults. Lancet (N. Am. Ed.). 340: 1188-1192.
47. Lehmann, E.D., D.K. Hopkins, A.J. Weissberger, R.G. Gosling, and P.H. Sönksen. 1993. Aortic extensibility in growth hormone deficient adults (Letter). Lancet (N. Am. Ed.). 341:309.
48. Wennmalm, A., G. Benthin, A. Edlund, L. Jungersten, N. Kieler-Jensen, S. Lundin, U. Nathorst-Westfelt, A.S. Petersson, and F. Waagstein. 1993. Metabolism and excretion of nitric oxide in humans. Circ. Res. 73:1121-1127.
49. Bode-Böger, S.M., R.H. Böger, A. Creutzig, D. Tsikas, F.M. Gutzki, K. Alexander, and J.C. Frölich. 1994. L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin. Sci. (Lond.). 87:303-310.
50. Kanno, K., Y. Hirata, T. Emori, K. Ohta, S. Eguchi, T. Imai, and F. Marumo. 1992. L-arginine infusion induces hypotension and diuresis/natriuresis concomitant with increased urinary excretion of nitrite/nitrate and cyclic GMP in humans. Clin. Exp. Pharmacol. Physiol. 19:619-625.
51. Drexler, H., A.M. Zeiher, K. Meinzer, and H. Just. 1991. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet (N. Am. Ed.). 338:1546-1550.
52. Tsao, P.S., G. Theilmeier, S.H. Singer, L.L.K. Leung, and J.P Cooke. 1994. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler. Thromb. 14:1529-1533.
53. Kubes, P., M. Suzuki, and D.N. Ganger. 1991. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA. 88:4651-4655.
54. Tsao, P.S., L.M. McEvoy, H. Drexler, E.C. Butcher, and J.P. Cooke. 1994. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation. 89:2176-2182.
55. Böger, R.H., S.M. Bode-Böger, and J.C. Frölich. 1996. The L-arginine-nitric oxide pathway. Role in atherosclerosis and therapeutic implications. Atherosclerosis. In press.
56. Myers, P.R., T.F. Wright, M.A. Tanner, and R.E. Ostlund, Jr. 1994. The effects of native and oxidized LDL on EDRF bioactivity and nitric oxide production in vascular endothelium. J. Lab. Clin. Med. 124:672-683.
57. Pohl, U., N. Heydari, and J. Galle. 1995. Effects of LDL on intracellular free calcium and nitric oxide-dependent cGMP formation in porcine endothelial cells. Atherosclerosis. 117:169-178.
58. Motani, A., L. Forster, S. Tull, E.E. Anggard, and G.A.A. Ferns. 1996. Insulin-like growth factor-I modulates monocyte adhesion to EAhy 926 endothelial cells. Int. J. Exp. Pathol. 77:31-35.
59. Mügge, A., R. Brandes, R.H. Böger, A. Dwenger, S.M. Bode-Böger, S. Kienke, J.C. Frölich, and P.R. Lichtlen. 1994. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 24:994-998.